4-溴-2-甲基嘧啶 | 1114560-76-7

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-溴-2-甲基嘧啶
• 英文名称: 4-bromo-2-methylpyrimidine
• CAS: 1114560-76-7
• 化学式: C₅H₅BrN₂
• 分子量: 173.012
• InChiKey: OJPQVYZLQGRFSO-UHFFFAOYSA-N

物化性质

• 沸点：
  195.2±13.0 °C(Predicted)
• 密度：
  1.596±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-methylpyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-methylpyrimidine
CAS number: 1114560-76-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5BrN2
Molecular weight: 173.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-甲基嘧啶 在 copper(l) iodide 、 四(三苯基膦)钯 、 lithium chloride 作用下， 以 1,4-二氧六环 为溶剂， 反应 15.0h， 生成 tert-butyl (S)-12-fluoro-4-(2-methylpyrimidin-4-yl)-7a,13-dihydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine-14(8H)-carboxylate
  参考文献：
  名称：

  [EN] MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
  [FR] DÉRIVÉS D'AZOLOPYRIDINE MACROCYCLIQUES UTILISÉS EN TANT QUE MODULATEURS EED ET PRC2

  摘要：

  本发明涉及用于治疗与Embryonic Ectoderm Development (EED)和/或Polycomb Repressive Complex 2 (PRC2)相关的疾病和障碍的调节剂，是式(I)所示的宏环唑啉衍生物及其组合物，或其药用可接受的盐、前药、溶剂化物、水合物、对映体、异构体或互变异构体，其中X1、X2、X3、A1、A2、Y、R1、R2、R3和R4如本文所述。

  公开号：

  WO2020190754A1
• 作为产物：
  描述：

  2-甲基嘧啶 在 2,2,6,6-四甲基哌啶 、 2-氯丙烷 、 magnesium 、 lithium chloride 、 溴 、 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以18.8%的产率得到4-溴-2-甲基嘧啶
  参考文献：
  名称：

  一种2,4-取代嘧啶的制备方法

  摘要：

  本发明属于化合物合成技术领域，具体涉及一种2,4‑取代嘧啶的制备方法。该方法包括以下步骤：1）将2‑取代嘧啶溶于四氢呋喃中，在‑60—‑78℃下滴加TMP.MgCl.LiCl，滴加1h后加入无水氯化锌，升温至室温，滴加卤素，2h后加入盐酸溶液淬灭反应；2）反应的反应液以乙酸乙酯萃取，有机层干燥浓缩，柱层析纯化即得产品。本发明与现有技术相比，以2‑取代嘧啶为原料时能特异性的选择4位取代，同时不产生5位取代的副产物，具有选择性好、产物单一、易于提纯的特点，具有反应条件温和、反应速率快等优点。

  公开号：

  CN109761908A

文献信息

• [EN] HETEROARYLBENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLBENZIMIDAZOLE
  申请人：BAYER PHARMA AG

  公开号：WO2017102091A1

  公开（公告）日：2017-06-22

  The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式（I）中的杂环芳基苯并咪唑化合物，其中R1、R2、R3、R4和R5如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或炎症性疾病的药物组合物，作为唯一活性成分或与其他活性成分组合使用。
• Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases
  申请人：MACSÁRI István

  公开号：US20120122843A1

  公开（公告）日：2012-05-17

  The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.

  本发明涉及式(I)的新化合物及其药用盐，包括含有该化合物的药物组合物，制备该化合物的方法，以及它们作为治疗和/或预防Aβ相关疾病的药物的用途。
• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLE DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015153720A1

  公开（公告）日：2015-10-08

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开通常涉及能够抑制AAK1（适配器相关激酶1）的化合物、包含该化合物的组合物以及抑制AAK1的方法。
• Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists
  作者：Samuel Hintermann、Christine Guntermann、Henri Mattes、David A. Carcache、Juergen Wagner、Anna Vulpetti、Andreas Billich、Janet Dawson、Klemens Kaupmann、Joerg Kallen、Rowan Stringer、David Orain

  DOI：10.1002/cmdc.201600500

  日期：2016.12.16

  10 ((S)‐N‐(8‐((4‐(cyclopentanecarbonyl)‐3‐methylpiperazin‐1‐yl)methyl)‐7‐methylimidazo[1,2‐a]pyridin‐6‐yl)‐2‐methylpyrimidine‐5‐carboxamide) and 33 ((S)‐N‐(8‐((4‐(5‐(tert‐butyl)‐1,2,4‐oxadiazol‐3‐yl)‐3‐methylpiperazin‐1‐yl)methyl)‐7‐methylimidazo[1,2‐a]pyridin‐6‐yl)‐2‐methylpyrimidine‐5‐carboxamide). Both derivatives showed good pharmacological potencies in biochemical and cell‐based assays combined

  视黄酸相关的孤儿受体γt（RORγt）是促炎性Th17细胞因子产生的关键转录因子，其可引发多种自身免疫性疾病。尽管已经报道了各种各样的化学系列，但是在RORγt抑制剂领域将高效能与良好的理化特性相结合一直是非常具有挑战性的任务。根据现有的化学结构并结合内部知识，设计了一系列新的三唑并咪唑并吡啶RORγt反向激动剂。此外，还研究了用五元杂环取代末端的环戊酰胺代谢新点。通过我们的努力，我们确定了最佳的6,7,8-取代的咪唑并[1,2- a ]吡啶核体系和5-叔丁基1,2,4-叔二唑丁基作为环戊酰胺的替代品，导致化合物10（（S）-N-（8-（（4-（环戊烷羰基）-3-甲基哌嗪-1-基）甲基）-7-甲基咪唑[ 1,2-一个]吡啶-6-基）-2-甲基嘧啶-5-甲酰胺）和33（（小号） - ñ - （8 - （（4-（5-（叔丁基）-1,2,4- 4-恶二唑-3-基）-3-甲基哌嗪-1-基）甲基）-7-甲基咪唑并[1
• 一种化合物及其制备方法和应用
  申请人：山东师范大学

  公开号：CN110746479B

  公开（公告）日：2021-01-08

  本发明提供了一种化合物及其制备方法和应用，该化合物具有式(I)所示结构：其中，R为未被取代的或被取代基取代的含氮杂环基；所述含氮杂环基为五元或六元含氮脂杂环或含氮芳香杂环；所述取代基选自烷基、卤代烷基、羧基、卤素；以及，本发明还提供了式(I)化合物的药学上可接受的盐。本发明的化合物对胆管癌细胞QBC‑939和人胰腺癌细胞PANC‑1增殖具有较好的抑制活性，本发明化合物在0.2ug/mL对胆管癌细胞QBC‑939和人胰腺癌细胞PANC‑1增殖的抑制率普遍都高于80％，现活性远高于临床应用的氟尿嘧啶。